Cervical Cancer is the fourth most common cause of cancer death in women worldwide. There are over half a million new cases diagnosed each year, 85% of which in developing regions.
CellDetect Cervical offers a new standard for the screening of women at risk of developing cervical cancer. Designed to simplify and expedite the microscopic examination of cervical smears while relying on standard lab equipment and processes, CellDetect addresses key
unmet needs in markets where cervical cancer still represents a significant healthcare burden.
CellDetect Cervical is approved in Europe, Israel and China. Micromedic is currently performing pilots in India and other territories.